検索結果
-
AV-001 アナウンスについて https://www.businesswire.com/news/home/20231114795277/en/Vasomune-and-AnGes-Announce-Drug-Candidate-AV-001-Receives-Positive-Recommendation-from-the-IDSMB-for-AV001-004-Phase-2a-Study https://www.morningstar.com/news/business-wire/20240415866329/american-thoracic-society-selects-vasomune-therapeutics-inc-to-present-the-av-001-development-update-at-the-2024-respiratory-innovation-summit ↓ ファースト・イン・クラス(FIC)、ベスト・イン・クラスと何が違う? https://bio.nikkeibp.co.jp/atcl/report/16/011900001/22/07/24/00412/ https://clinicalresearch.som.uci.edu/clinical-trials/CCR-22-28 https://www.researchgate.net/figure/AV-001-treatment-significantly-increases-synaptogenesis-in-middle-aged-rats-subjected_fig4_360418156 https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.072706 https://synapse.patsnap.com/drug/462a8ae4dab743f8b67c40e7065ae168#trialResult
-
AV-001 アナウンスについて https://www.businesswire.com/news/home/20231114795277/en/Vasomune-and-AnGes-Announce-Drug-Candidate-AV-001-Receives-Positive-Recommendation-from-the-IDSMB-for-AV001-004-Phase-2a-Study https://www.morningstar.com/news/business-wire/20240415866329/american-thoracic-society-selects-vasomune-therapeutics-inc-to-present-the-av-001-development-update-at-the-2024-respiratory-innovation-summit ↓ ファースト・イン・クラス(FIC)、ベスト・イン・クラスと何が違う? https://bio.nikkeibp.co.jp/atcl/report/16/011900001/22/07/24/00412/ https://clinicalresearch.som.uci.edu/clinical-trials/CCR-22-28 https://www.researchgate.net/figure/AV-001-treatment-significantly-increases-synaptogenesis-in-middle-aged-rats-subjected_fig4_360418156 https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.072706 https://synapse.patsnap.com/drug/462a8ae4dab743f8b67c40e7065ae168#trialResult
-
AV-001 について https://www.businesswire.com/news/home/20231114795277/en/Vasomune-and-AnGes-Announce-Drug-Candidate-AV-001-Receives-Positive-Recommendation-from-the-IDSMB-for-AV001-004-Phase-2a-Study https://www.morningstar.com/news/business-wire/20240415866329/american-thoracic-society-selects-vasomune-therapeutics-inc-to-present-the-av-001-development-update-at-the-2024-respiratory-innovation-summit ↓ ファースト・イン・クラス(FIC)、ベスト・イン・クラスと何が違う? https://bio.nikkeibp.co.jp/atcl/report/16/011900001/22/07/24/00412/ https://clinicalresearch.som.uci.edu/clinical-trials/CCR-22-28 https://www.researchgate.net/figure/AV-001-treatment-significantly-increases-synaptogenesis-in-middle-aged-rats-subjected_fig4_360418156 https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.072706 https://synapse.patsnap.com/drug/462a8ae4dab743f8b67c40e7065ae168#trialResult
-
AV-001 について https://www.businesswire.com/news/home/20231114795277/en/Vasomune-and-AnGes-Announce-Drug-Candidate-AV-001-Receives-Positive-Recommendation-from-the-IDSMB-for-AV001-004-Phase-2a-Study https://www.morningstar.com/news/business-wire/20240415866329/american-thoracic-society-selects-vasomune-therapeutics-inc-to-present-the-av-001-development-update-at-the-2024-respiratory-innovation-summit ↓ ファースト・イン・クラス(FIC)、ベスト・イン・クラスと何が違う? https://bio.nikkeibp.co.jp/atcl/report/16/011900001/22/07/24/00412/ https://clinicalresearch.som.uci.edu/clinical-trials/CCR-22-28 https://www.researchgate.net/figure/AV-001-treatment-significantly-increases-synaptogenesis-in-middle-aged-rats-subjected_fig4_360418156 https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.072706 https://synapse.patsnap.com/drug/462a8ae4dab743f8b67c40e7065ae168#trialResult
-
AV-001 について https://www.businesswire.com/news/home/20231114795277/en/Vasomune-and-AnGes-Announce-Drug-Candidate-AV-001-Receives-Positive-Recommendation-from-the-IDSMB-for-AV001-004-Phase-2a-Study https://www.morningstar.com/news/business-wire/20240415866329/american-thoracic-society-selects-vasomune-therapeutics-inc-to-present-the-av-001-development-update-at-the-2024-respiratory-innovation-summit ↓ ファースト・イン・クラス(FIC)、ベスト・イン・クラスと何が違う? https://bio.nikkeibp.co.jp/atcl/report/16/011900001/22/07/24/00412/ https://clinicalresearch.som.uci.edu/clinical-trials/CCR-22-28 https://www.researchgate.net/figure/AV-001-treatment-significantly-increases-synaptogenesis-in-middle-aged-rats-subjected_fig4_360418156 https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.072706 https://synapse.patsnap.com/drug/462a8ae4dab743f8b67c40e7065ae168#trialResult
av-001 アナウンスについ…
2024/05/27 10:42
av-001 アナウンスについて https://www.businesswire.com/news/home/20231114795277/en/Vasomune-and-AnGes-Announce-Drug-Candidate-AV-001-Receives-Positive-Recommendation-from-the-IDSMB-for-AV001-004-Phase-2a-Study https://www.morningstar.com/news/business-wire/20240415866329/american-thoracic-society-selects-vasomune-therapeutics-inc-to-present-the-av-001-development-update-at-the-2024-respiratory-innovation-summit ↓ ファースト・イン・クラス(FIC)、ベスト・イン・クラスと何が違う? https://bio.nikkeibp.co.jp/atcl/report/16/011900001/22/07/24/00412/ https://clinicalresearch.som.uci.edu/clinical-trials/CCR-22-28 https://www.researchgate.net/figure/AV-001-treatment-significantly-increases-synaptogenesis-in-middle-aged-rats-subjected_fig4_360418156 https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.072706 https://synapse.patsnap.com/drug/462a8ae4dab743f8b67c40e7065ae168#trialResult